ML criticality in clinical outcome across cancer types.

Slides:

Advertisements

Similar presentations

Somatic Mutation Distributions Determining Cut-offs Supp. Figure 5.

Advertisements

Infrastructure for Sharing Very Large Data Sets Antonio M. Ferreira, PhD Executive Director, Center for Simulation and Modeling.

Cancer Card Game Answers etc.

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

INCLUDE THE NAME OF YOUR TYPE OF CANCER! MAKE SURE YOU INCLUDE SEVERAL APPROPRIATE PICTURES IN YOUR POWERPOINT! ONLY POINT FORM IS ALLOWED ON SLIDES (NO.

Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.

Cancer “whiteboard” presentation ●Name of cancer (what type), where can it occur? ●Function of body part that it affects ●Causes (genetic, environmental…)?

Cancer Facts MS JYOTI SHAH CONSULTANT UROLOGICAL SURGEON SOURCE: CANCER RESEARCH UK.

CANCER Tomsk CONTENTS INTRODUCTION THE MOST COMMON TYPES OF CANCER SKIN CANCER LUNG CANCER KIDNEY CANCER BREAST CANCER THYROID CANCER TREATMENT.

Qualified Patient Criteria Combinations (Female and Male) Personal History of (any one of the below): Breast or Ovarian cancer (any age) Prostate or Pancreatic.

PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer Zoran Gatalica1*, Jude.

Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling Nuala McCabe,1,2 Laura A. Knight, 2 Andrena McCavigan,2.

From: Epigenetic instability of imprinted genes in human cancers

CANCER Carbon Co. Luzerne Schuylkill Pennsylvania TABLE 1. Distribution of Cancers by Type for Tamaqua Study Counties and Pennsylvania Based on

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other.

Glioblastoma Multiforme SSEA1+ CD133+

(A) Schematic diagrams demonstrating the HER2 mutational heterogeneity among and between cases of invasive breast cancer (n=963), bladder urothelial cancer.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Volume 31, Issue 4, Pages e8 (April 2017)

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other.

Comparison (R) of the mean observed to expected dinucleotide distribution for (A) genes with MAE vs. Comparison (R) of the mean observed to expected dinucleotide.

The Functional Impact of Alternative Splicing in Cancer

Volume 16, Issue 10, Pages (September 2016)

Molecular Signatures for Tumor Classification

Nicholas McGranahan, Charles Swanton Cell

Volume 18, Issue 8, Pages (August 2017)

Distribution of mutations in different groups of genes, in cancer with extreme ML values. Distribution of mutations in different groups of genes, in cancer.

Empirical mutation-selection phase diagram of tumor evolution.

ERVmap reveals additional breast cancer-associated ERVs that correlate with cytolytic activity. ERVmap reveals additional breast cancer-associated ERVs.

Empirical mutation-selection phase diagram of tumor evolution.

Distribution of mutations in different groups of genes, in cancer with extreme ML values. Distribution of mutations in different groups of genes, in cancer.

Volume 32, Issue 2, Pages e6 (August 2017)

Immunity-related genes and enhancers are enriched for eQTLs.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Hotspot mutations drive clustering of tumor types

CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia by Ying-Ping Jiang, Bob Y. Liu, Quan Zheng,

Volume 18, Issue 8, Pages (August 2017)

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Malignancy-associated dermatomyositis: Retrospective case–control study from a single tertiary care center Laura Kooistra, BS, Claudia Ricotti, BS, Fabrizio.

Volume 165, Issue 1, Pages (March 2016)

Volume 29, Issue 5, Pages (May 2016)

Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant p53-null cells. Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant.

Volume 13, Issue 2, Pages (October 2015)

Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes Qiancheng Shen, Feixiong Cheng,

The Functional Impact of Alternative Splicing in Cancer

When Genome Maintenance Goes Badly Awry

Volume 8, Issue 3, Pages (August 2014)

Volume 7, Issue 6, Pages (June 2014)

Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors

The Methylation Landscape of Human Cancers

Volume 21, Issue 13, Pages (December 2017)

Volume 29, Issue 5, Pages (May 2016)

Peilin Jia, Zhongming Zhao Cell Reports

The Mucinous Lung Tumor Signature is highly enriched in colorectal, stomach, pancreatic, lung (adenocarcinoma; LUAD), and breast cancers The Mucinous Lung.

Identification of candidate genes within the 1q32 locus.

Consistency of results across images and time.

Volume 13, Issue 6, Pages (November 2015)

NRG1 rearrangements are found in multiple solid tumors.

Four Key Steps Control Glycolytic Flux in Mammalian Cells

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

Distribution of FGFR aberrancies in urothelial cancers.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Gene expression patterns of SLC and ABC transporters in normal and tumor tissues. Gene expression patterns of SLC and ABC transporters in normal and tumor.

MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. MGA271 mediates in vitro ADCC across a panel.

lncRNA HOXA11-AS is overexpressed in gastric cancer tissues.

Cell lines from hematologic cancers, including multiple myeloma (MM), AML, and DLBCL, exhibit a strong dependency on MCL1 for survival. Cell lines from.

Correlations between comutations of HRR-BER or HRR-MMR and tumor mutational burden, neoantigen load, and MSI-H. Correlations between comutations of HRR-BER.

Collin Tokheim, Rachel Karchin Cell Systems

Superenhancers near the KLF5 gene are focally amplified in diverse cancer types. Superenhancers near the KLF5 gene are focally amplified in diverse cancer.

FGFR2 amplification in gastric and colon cancer cell lines is associated with response to NVP-BGJ398. FGFR2 amplification in gastric and colon cancer cell.

Presentation transcript:

ML criticality in clinical outcome across cancer types. ML criticality in clinical outcome across cancer types. Log distributions of the number of N mutations per proteome/sample in each cancer type (Top) and the corresponding results of Cox regression analysis (Bottom) are shown. Statistical significance is indicated for three thresholds: *P < 0.1, **P < 0.01, and ***P < 0.001. The KM results (SI Appendix, Fig. S4) are superimposed; the cases where a low (L, blue) or high (H, red) number of mutations was associated with better survival (P ≤ 0.1) are highlighted. Gray letters (L or H) indicate an observed but not significant (P > 0.1) correlation. Complementing Cox regression models stratified by cancer types are summarized in Table 1. Cancers are ordered by the median ML (N). Oncotree codes: (1) Thym, thymoma; (2) Laml, AML; (3) Thca, thyroid carcinoma; (4) Pcpg, pheochromocytoma and paraganglioma; (5) Lgg, brain lower grade glioma; (6) Brca, breast invasive carcinoma; (7) Prad, prostate adenocarcinoma; (8) Sarc, sarcoma; (9) Ov, ovarian serous cystadenocarcinoma; (10) Paad, pancreatic adenocarcinoma; (11) Kirc, kidney renal clear cell carcinoma; (12) Kirp, kidney renal papillary cell carcinoma; (13) Gbm, glioblastoma; (14) Tgct, testicular germ cell cancer; (15) Lihc, liver hepatocellular carcinoma; (16) Cesc, cervical squamous cell carcinoma and endocervical adenocarcinoma; (17) Hnsc, head and neck squamous cell carcinoma; (18) Stad, stomach adenocarcinoma; (19) Luad, lung adenocarcinoma; (20) Blca, bladder urothelial carcinoma; (21) Esca, esophageal carcinoma; (22) Lusc, lung squamous cell carcinoma; (23) Skcm, skin cutaneous melanoma. Erez Persi et al. PNAS 2018;115:47:E11101-E11110 ©2018 by National Academy of Sciences